Xilio Therapeutics (NASDAQ:XLO – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares Xilio Therapeutics and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xilio Therapeutics | -34.06% | -71.99% | -20.43% |
| Korro Bio | N/A | -114.26% | -68.57% |
Earnings & Valuation
This table compares Xilio Therapeutics and Korro Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xilio Therapeutics | $43.77 million | 1.39 | -$35.04 million | ($1.64) | -5.62 |
| Korro Bio | $6.39 million | 20.31 | -$117.26 million | ($10.00) | -0.88 |
Xilio Therapeutics has higher revenue and earnings than Korro Bio. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.13, indicating that its share price is 213% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Xilio Therapeutics and Korro Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xilio Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Korro Bio has a consensus price target of $16.50, indicating a potential upside of 87.29%. Given Korro Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than Xilio Therapeutics.
Institutional & Insider Ownership
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 7.4% of Xilio Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
